- Full-Year and Q4 2018 GAAP Net Revenue Driven by Growth in Top Promoted Products Including BOTOX®, VRAYLAR®, JUVÉDERM® Collection of Fillers and Lo LOESTRIN® -">- Full-Year and Q4 2018 GAAP Net Revenue Driven by Growth in Top Promoted Products Including BOTOX®, VRAYLAR®, JUVÉDERM® Collection of Fillers and Lo LOESTRIN® -- Continues to Advance R&D Pipeline on Key Programs Including Cariprazine for Bipolar Depression, Ubrogepant for Migraine and Bimatoprost SR for Glaucoma -">- Continues to Advance R&D Pipeline on Key Programs Including Cariprazine for Bipolar Depression, Ubrogepant for Migraine and Bimatoprost SR for Glaucoma -
Executive Commentary
"Allergan posted another quarter of strong results to close out 2018, underscoring our focus on execution, financial discipline and the strength of our core business which grew 8.3 percent. Our anchor brands BOTOX® Cosmetic, BOTOX® Therapeutic, VRAYLAR®, JUVÉDERM®, Lo LOESTRIN®, CoolSculpting® and LINZESS® added nearly $1 billion in new revenue to our core business in 2018," said Brent Saunders, Chairman and CEO of Allergan. "I'm also proud of the significant advances we have made in our R&D pipeline with positive clinical results reported from six late-stage development programs. We look to build on that progress in 2019."vraylar oké, de irnak az esmyaról is? hát ezen eredmények alapján nagyon kellene igyekezniük az esmyával
Executive Commentary
"Allergan posted another quarter of strong results to close out 2018, underscoring our focus on execution, financial discipline and the strength of our core business which grew 8.3 percent. Our anchor brands BOTOX® Cosmetic, BOTOX® Therapeutic, VRAYLAR®, JUVÉDERM®, Lo LOESTRIN®, CoolSculpting® and LINZESS® added nearly $1 billion in new revenue to our core business in 2018," said Brent Saunders, Chairman and CEO of Allergan. "I'm also proud of the significant advances we have made in our R&D pipeline with positive clinical results reported from six late-stage development programs. We look to build on that progress in 2019."vraylar oké, de irnak az esmyaról is? hát ezen eredmények alapján nagyon kellene igyekezniük az esmyával
Richter topik
Az elemzők hosszabb távon vonzónak tartják a Richtert, ezért ajánlásukat felhalmozásra módosították. A célárfolyamot viszont a korábbi 47 580 forintról 46 310-ra rontották, azzal párhuzamosan, hogy a belföldi értékesítési előrejelzéseiket is lejjebb vitték.